🇺🇸 FDA
Pipeline program

SPD503-AM

SPD503-313

Phase 3 small_molecule completed

Quick answer

SPD503-AM for ADHD is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
ADHD
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials